Allogeneic human umbilical cord blood haematopoietic progenitor cell therapy - StemCyte
Alternative Names: HPC-cord blood - StemCyte; RegeneCyte; REGENECYTELatest Information Update: 24 Sep 2025
At a glance
- Originator StemCyte
- Class Haematopoietic stem cells therapies
- Mechanism of Action Cell replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Registered Haematological disorders; Immunological disorders
- Phase II Post acute COVID 19 syndrome
Most Recent Events
- 23 Sep 2025 StemCyte International plans a phase III trial for Post acute COVID-19 syndrome in unknown location (NCT07184385)
- 20 Dec 2024 StemCyte is in rolling discussion with US FDA to move forward with the next phase of clinical trials
- 20 Dec 2024 Efficacy and adverse events data from a phase IIa trial in Post acute COVID-19 syndrome released by StemCyte